期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Development ofLeishmania vaccines:predicting the future from past and present experience 被引量:2
1
作者 Joshua Muli Mutiso John Chege Macharia +3 位作者 maria ndunge kiio James Maina Ichagichu Hitler Rikoi Michael Muita Gicheru 《The Journal of Biomedical Research》 CAS 2013年第2期85-102,共18页
Leishmaniasis is a disease that ranges in severity infection. Resistance to infection is associated with from skin lesions to serious disfigurement and fatal systemic a T-helper-1 immune response that activates macrop... Leishmaniasis is a disease that ranges in severity infection. Resistance to infection is associated with from skin lesions to serious disfigurement and fatal systemic a T-helper-1 immune response that activates macrophages to kill the intracellular parasite in a nitric oxide-dependent manner. Conversely, disease progression is generally associated with a T-helper-2 response that activates humoral immunity. Current control is based on chemothera- peutic treatments which are expensive, toxic and associated with high relapse and resistance rates. Vaccination remains the best hope for control of all forms of the disease, and the development of a safe, effective and affordable antileishmanial vaccine is a critical global public-health priority. Extensive evidence from studies in animal models indicates that solid protection can be achieved by immunization with defined subunit vaccines or live-at- tenuated strains of Leishmania. However, to date, no vaccine is available despite substantial efforts by many laboratories. Major impediments in Leishmania vaccine development include: lack of adequate funding from national and international agencies, problems related to the translation of data from animal models to human disease, and the transition from the laboratory to the field. Furthermore, a thorough understanding of protective immune responses and generation and maintenance of the immunological memory, an important but least-studied aspect of antiparasitic vaccine development, during Leishmania infection is needed. This review focuses on the progress of the search for an effective vaccine against human and canine leishmaniasis. 展开更多
关键词 LEISHMANIA LEISHMANIASIS VACCINE IMMUNIZATION immune response
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部